Gene therapy for CNS conditions promises great potential cures. But so far development has been slowed by lack of ability to target and access the right cells, and limited gene expression. Now, the nVector platform can help overcome those barriers.
More targeted — first platform to target glia (immune) and neuron cells by cell type.
Better distribution – throughout the spinal cord and brain from single injection.
More opportunity – 10 MM novel capsid library can support a wide array of CNS gene therapy initiatives.